Lorazepam (Ativan): Independent Evidence on Anxiety, Seizures & Withdrawal

Table of contents

• Evidence summary
• What lorazepam is
• How it works
• What it is prescribed for
• What works and what does not
• Benefits by claim
• Risks and all side effects
• All interactions
• Who should avoid lorazepam
• Dosage and how to take it
• Follow the money: who makes it and who funded the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator or government body; 2 = academic, Cochrane or publicly funded team with no declared commercial funding for the work; 3 = independent authors analysing mostly manufacturer-run trials, or minor declared industry ties; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D.

What lorazepam is

Lorazepam is a benzodiazepine. The US label describes Ativan as "an antianxiety agent" (FDA Ativan tablets label), and the injection label adds that it has "antianxiety, sedative, and anticonvulsant effects" (FDA Ativan injection label). By half-life it sits in the middle of the class: about 12 hours, shorter than diazepam and longer than midazolam.

• Brand names: Ativan (tablets and injection). In the US there is also Loreev XR, an extended-release capsule approved on 27 August 2021 for adults with anxiety disorders who are already on stable three-times-daily lorazepam tablets (Loreev XR label; openFDA NDA 214826). The NHS lists Ativan as the brand name (NHS), but the UK medicines compendium lists only generic lorazepam products from nine companies (eMC listing).
• First US approvals: Ativan tablets (NDA 017794) on 30 September 1977 and Ativan injection (NDA 018140) on 25 July 1980 (Drugs@FDA; openFDA).
• Originator and current owners: The earliest label we retrieved, from 2007, reads "Manufactured by: Wyeth Pharmaceuticals Inc. Philadelphia" and "Distributed by: Biovail Pharmaceuticals, Inc." (FDA label archive, 2007). The tablet NDA is now held by Bausch Health (Laval, Quebec, Canada), and the tablets are made in Steinbach, Manitoba (FDA label). The injection NDA is held by Hikma (injection label). We did not confirm the name of the 1977 applicant from a primary document.
• Generic status: Off-patent. openFDA lists 16 generic (ANDA) lorazepam applications (openFDA query).
• US status: Prescription-only, Schedule IV controlled substance (FDA label).
• UK status: Prescription-only medicine, available on the NHS as 0.5 mg, 1 mg and 2.5 mg tablets and a 1 mg/ml oral liquid (NHS), plus an injection for hospital use. It is a Class C, Schedule 4 Part 1 controlled drug (Home Office controlled drugs list).

How it works

Lorazepam binds to the benzodiazepine site on the GABA_A receptor complex. It "does not displace GABA" but enhances its effect (FDA injection label). GABA is the brain's main calming, inhibitory messenger. The NHS explains it as increasing "a calming chemical in your brain" which, "depending on your health condition", can make you calmer, relieve anxiety or stop a seizure (NHS).

Pharmacokinetics that matter in practice (FDA tablets label; UK SmPC 5.2):

• Absorption: Absolute bioavailability is 90%, with peak blood levels about 2 hours after a tablet. The NHS says tablets and liquid start to work in about 20 to 30 minutes, reach full sedating effect after 1 to 1.5 hours, and last about 6 to 8 hours.
• Half-life: About 12 hours. Its main metabolite, lorazepam glucuronide, has a half-life of about 18 hours but "no demonstrable central nervous system (CNS) activity".
• Metabolism: Lorazepam is cleared by a "simple one-step process" of glucuronidation, not mainly by the liver's CYP450 enzymes. This is why it has fewer enzyme-based drug interactions than alprazolam or diazepam. The exceptions, valproate and probenecid, block glucuronidation and roughly double exposure.
• Accumulation: "There is no evidence of accumulation of lorazepam on administration up to 6 months." Age had no significant effect on its kinetics in comparative studies, although clearance fell by 20% in one study of 15 people aged 60 to 84.

What it is prescribed for

Licensed indications differ by product and country

Sources: FDA tablets label; FDA injection label; UK tablets SmPC 4.1; UK injection SmPC 4.1.

Where guidelines place it

• Status epilepticus (NICE NG217, 7.1.3): "give a benzodiazepine (buccal midazolam or rectal diazepam) immediately as first-line treatment in the community or use intravenous lorazepam if intravenous access and resuscitation facilities are immediately available." The committee chose IV lorazepam as the first-choice hospital treatment "because of its rapid action and because it causes less respiratory depression and sedation than other drugs". If two benzodiazepine doses fail, NICE moves to levetiracetam, phenytoin or sodium valproate (NICE NG217). This makes lorazepam a first-line hospital treatment.
• GAD (NICE CG113, 1.2.26): "Do not offer a benzodiazepine for the treatment of GAD in primary or secondary care except as a short-term measure during crises" (NICE CG113). This is crisis-only. An SSRI and psychological therapy come first.
• Panic disorder (NICE CG113, 1.3.20): "Benzodiazepines are associated with a less good outcome in the long term and should not be prescribed for the treatment of individuals with panic disorder." This is not recommended.
• WHO mhGAP (2023), ANX6: "Benzodiazepines are not recommended for the treatment of adults with generalized anxiety disorder (GAD) and/or panic disorder." Emergency use for acute, severe anxiety is allowed "only as a short-term (3–7 days maximum) measure". This is a strong recommendation on low-certainty evidence (WHO mhGAP).
• Older adults (AGS Beers 2023): Avoid benzodiazepines, including lorazepam (strong recommendation). The criteria say they "may be appropriate for seizure disorders ... benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia" (AGS Beers 2023).
• NHS patient guidance: For anxiety, a doctor "will usually start you on" an SSRI such as sertraline, paroxetine or escitalopram, alongside talking therapies (NHS).

What works and what does not

Benefits by claim

Status epilepticus: the strongest evidence

NICE defines convulsive status epilepticus as seizures lasting 5 minutes or more, and calls it "a medical emergency that needs immediate treatment" (NICE NG217). This is where lorazepam's evidence is best, and most of it was produced by public funders rather than the drug's sellers.

• Cochrane review, adults and mixed ages (Prasad et al., 2014): 18 randomised trials with 2,755 participants (Prasad 2014). Risk of seizures not stopping:
  • IV lorazepam vs placebo: RR 0.52 (95% CI 0.38 to 0.71).
  • IV lorazepam vs IV diazepam: RR 0.64 (95% CI 0.45 to 0.90). Lorazepam also carried a lower risk of needing a different drug or general anaesthesia (RR 0.63).
  • IV lorazepam vs IV phenytoin: RR 0.62 (95% CI 0.45 to 0.86).
  • Levetiracetam and lorazepam were "equally effective in aborting seizures" (RR 0.97, 95% CI 0.44 to 2.13).
  The authors concluded that "intravenous lorazepam is better than intravenous diazepam or intravenous phenytoin alone for cessation of seizures". They also cautioned that "the body of randomised evidence to guide clinical decisions is small".
• Paramedic trial (Alldredge et al., 2001): 205 adults with prolonged or repeated convulsions were randomised to IV lorazepam 2 mg, diazepam 5 mg or placebo. Status epilepticus had ended by arrival at hospital in 59.1%, 42.6% and 21.1% respectively. The adjusted odds ratio for lorazepam versus placebo was 4.8 (95% CI 1.9 to 13.0), and for lorazepam versus diazepam 1.9 (95% CI 0.8 to 4.4), which was not statistically significant. Breathing or circulation complications were numerically less common with either drug than with placebo (10.6%, 10.3% and 22.5%; P = 0.08), a reminder that untreated seizures are dangerous in themselves (Alldredge 2001).
• Before hospital, the injection route matters (RAMPART, 2012): In 893 children and adults treated by paramedics, seizures were absent on arrival without rescue therapy in 73.4% given intramuscular midazolam and 63.4% given IV lorazepam. The key difference was speed: median time to active treatment was 1.2 minutes for the muscle injection and 4.8 minutes for the IV route, even though IV lorazepam then worked faster once given (1.6 vs 3.3 minutes). Intubation rates were similar, at 14.1% and 14.4% (Silbergleit 2012).
• Children (Chamberlain et al., 2014; McTague et al., Cochrane 2018): In a 273-child US trial, seizures stopped in 72.9% given lorazepam and 72.1% given diazepam. Assisted ventilation was needed in 17.6% and 16.0%, and lorazepam caused more sedation (66.9% vs 50%). The authors concluded the findings "do not support the preferential use of lorazepam" (Chamberlain 2014). The paediatric Cochrane review found IV lorazepam and diazepam similar for seizure cessation (RR 1.04, 3 trials, 414 children, low-quality evidence), but with less respiratory depression on lorazepam (RR 0.72, 95% CI 0.55 to 0.93, moderate quality) (McTague 2018).
• The licensing trials: The US injection label summarises two sponsor trials in 177 patients. In a double-blind comparison, 24 of 30 (80%) responded to lorazepam and 16 of 28 (57%) to diazepam (p = 0.04). After additional doses the figures were 93% and 86%, "a difference that was not statistically significant". The label itself says the study "cannot speak reliably or meaningfully to the comparative performance" of the two drugs in real-world use (FDA injection label).

What this means clinically. The evidence clearly supports giving a benzodiazepine fast, and supports IV lorazepam where a line is already in place. NICE's committee noted that "the speed of delivery is more important than the type of benzodiazepine" (NICE NG217). That is why families and carers of people with epilepsy in the UK are usually given buccal midazolam or rectal diazepam rather than lorazepam.

Anxiety

The US tablet label contains no efficacy data at all. It simply states the indication and adds that "anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic" (FDA label). This reflects the drug's 1977 approval, before modern trial reporting.

• Class-level independent evidence: The largest network meta-analysis of GAD drugs (89 trials, 25,441 patients, no funding) found that "paroxetine and benzodiazepines were effective but also poorly tolerated when compared with placebo" (Slee 2019). For panic disorder, benzodiazepines beat placebo for response (RR 1.65, NNTB 4) on low-quality evidence with "probable publication bias" (Breilmann 2019).
• Lorazepam-specific data are thin: The 2023 Cochrane network meta-analysis of panic drugs named diazepam, alprazolam and clonazepam as the top-ranked benzodiazepines; its abstract does not report lorazepam (Guaiana 2023). The WHO's evidence review for panic disorder examined "alprazolam, adinazolam, clonazepam, diazepam and midazolam", not lorazepam (WHO mhGAP).
• Active-comparator data: Lorazepam was used as a comparison drug in pregabalin trials. In a pooled analysis of six such trials, the benzodiazepine arms (lorazepam 6 mg/day or alprazolam 1.5 mg/day, 299 patients) produced significant improvement in both psychic and somatic anxiety versus placebo, with significant improvement on 5 of 14 Hamilton Anxiety items (Lydiard 2010). These data came from a commercial development programme for a different drug.
• Long-term: Across 8 studies of 13 weeks or more (N = 1,228), there was no significant difference in HAM-A change between benzodiazepines and placebo (Shinfuku 2019).

The WHO reviewed this body of evidence and still recommended against benzodiazepines for GAD and panic, "since the GDG concluded that the risks of the intervention outweighed the benefits" (WHO mhGAP).

Before surgery and procedures

Lorazepam is licensed as a pre-medication to reduce anxiety and memory of the day of surgery. The US label says it is "most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall" (FDA injection label). The best independent test of routine use is the French PremedX trial. It randomised 1,062 adults under 70 having planned surgery under general anaesthesia to lorazepam 2.5 mg, no premedication or placebo:

• Patient satisfaction the next day was no better with lorazepam (index 72 vs 73 vs 71, P = .38), including in the most anxious patients.
• Time to removal of the breathing tube was longer (17 vs 12 vs 13 minutes).
• Early cognitive recovery was lower (51% vs 71% vs 64%).

The authors concluded their findings "suggest a lack of benefit with routine use of lorazepam as sedative premedication" (Maurice-Szamburski 2015). This does not rule out benefit for individual patients with severe procedural anxiety, but it undercuts routine use.

Placebo response and speed

In the out-of-hospital seizure trial, 21.1% of placebo patients stopped seizing before reaching hospital (Alldredge 2001), and in the pre-operative trial the placebo group's satisfaction was almost identical to the lorazepam group's (Maurice-Szamburski 2015). Lorazepam's sedative effect is easy to feel, which can break blinding in anxiety trials. Its onset is fast: 20 to 30 minutes for tablets, according to the NHS (NHS).

Risks and all side effects

The FDA boxed warning, summarised

Both US Ativan labels carry the class boxed warning that the FDA required in September 2020 (FDA 2020; FDA tablets label):

• Opioids: Using benzodiazepines with opioids "may result in profound sedation, respiratory depression, coma, and death". Combined prescribing should be reserved for patients "for whom alternative treatment options are inadequate". This warning was first added in August 2016, after emergency visits involving non-medical use of both drug types rose from 11 to 34.2 per 100,000 population between 2004 and 2011 (FDA 2016, archived).
• Abuse, misuse and addiction: These "can lead to overdose or death". Prescribers should assess each patient's risk before and throughout treatment. The Medication Guide warns: "You can develop an addiction even if you take ATIVAN exactly as prescribed."
• Dependence and withdrawal: Abrupt stopping or rapid dose reduction "may precipitate acute withdrawal reactions, which can be life-threatening". A gradual taper is required.

The FDA's 2020 review reported that US benzodiazepine-involved overdose deaths rose from 1,298 in 2010 to 11,537 in 2017, and that from 2013 to 2017, 55% of these deaths also involved prescription opioids. In 2019, lorazepam made up 20% of the estimated 92 million US benzodiazepine prescriptions, behind alprazolam (38%) and clonazepam (24%) (FDA 2020). In the UK, the MHRA told prescribers in March 2020 to "only prescribe benzodiazepines (or benzodiazepine-like drugs) and opioids together if there is no alternative" (MHRA Drug Safety Update).

Common side effects

The US label's frequencies come from a sample of about 3,500 treated patients with no placebo comparison given, so they cannot show how much is caused by the drug itself. The UK SmPC notes that side effects "are usually observed at the beginning of therapy" and often ease with continued use or a lower dose (UK SmPC 4.8).

Serious risks

Overdose. In mild cases overdose causes drowsiness, confusion and lethargy. With other CNS depressants or alcohol it can cause respiratory depression, coma and, "very rarely, death" (UK SmPC 4.9). The US label warns that the reversal drug flumazenil can trigger seizures and is contraindicated when a benzodiazepine was given to control status epilepticus (FDA label). An animal finding is also on the label: oesophageal dilation in rats given lorazepam for more than a year, of unknown clinical significance.

All interactions

Sources: FDA tablets label, Drug Interactions; UK SmPC 4.5; NHS; NHS common questions.

Who should avoid lorazepam

• Contraindicated (UK tablets): hypersensitivity to benzodiazepines; acute pulmonary insufficiency, respiratory depression or sleep apnoea; obsessional states; severe hepatic insufficiency (it may precipitate encephalopathy); myasthenia gravis; planning a pregnancy; and pregnancy "unless there are compelling reasons" (UK SmPC 4.3).
• Contraindicated (US): hypersensitivity and acute narrow-angle glaucoma for tablets (FDA label). The injection is also contraindicated in sleep apnoea, severe respiratory insufficiency (except in ventilated patients), intra-arterial use and premature infants (FDA injection label).
• People taking opioids, or with a current or past alcohol or drug problem. The NHS advises telling a doctor about any past problems with alcohol or recreational drugs, as "they may want to try you on a different medicine" (NHS).
• People with depression, suicidal thoughts or a personality disorder (NHS). Do not use alone for depression.
• Older adults: The Beers Criteria say avoid (strong recommendation), except in situations such as seizure disorders and procedures (Beers 2023). If used, the UK advises cutting the starting dose by about 50% (UK SmPC 4.2).
• Liver and kidney impairment: Lower doses may be enough. Contraindicated in severe hepatic insufficiency in the UK; caution in the US because it may worsen hepatic encephalopathy.
• Lung disease such as COPD, and balance problems or a risk of falls (NHS).
• Pregnancy: UK and US sources differ in emphasis. The UK tablet SmPC says benzodiazepines "should not be used during pregnancy, especially during the first and last trimesters" (SmPC 4.6). The NHS says lorazepam "can be taken during pregnancy" but that long use late in pregnancy may make the baby drowsy and cause withdrawal (NHS). The US label says observational studies "do not report a clear association" with major birth defects (FDA label). Decisions belong with the prescriber.
• Breastfeeding: The UK SmPC says mothers who are breastfeeding "should not take benzodiazepines". The NHS says you can usually take lorazepam if your baby is healthy, as it passes into milk in very small amounts, but advises against bed-sharing. The US label advises monitoring the infant for sedation and poor feeding.
• Children: Not for anxiety or insomnia. Pre-operative use only from age 5 in the UK.

Dosage and how to take it

Your prescriber sets the dose. The figures below are the official licensed adult ranges, not personal advice.

Sources: UK tablets SmPC 4.2; UK injection SmPC 4.2; NHS; FDA tablets label; FDA injection label.

• How long before it works: Tablets and liquid start working in about 20 to 30 minutes and last about 6 to 8 hours. An injection works much faster (NHS).
• How long to take it: For anxiety or sleep problems, usually "from a few days to 4 weeks". Before a procedure, usually no more than 2 doses (NHS). The UK SmPC says a strategy for ending treatment should be agreed before starting.
• If a higher dose is needed, the US label says the evening dose should be increased before the daytime doses.
• How to stop: Always with the prescriber, using a gradual taper. The UK SmPC says tapering from a high dose "may take in excess of weeks or months", and advises "a slow stepwise rate of reduction proportionate to the existing dose, so that decrements become smaller as the dose is lowered" (UK SmPC 4.4). NICE adds that, for a benzodiazepine with a short half-life, prescribers should consider switching to one with a longer half-life, and should apply any published schedule flexibly (NICE NG215, 1.5.11–1.5.14). If withdrawal symptoms appear, the taper may be paused or stepped back before continuing more slowly (FDA label).
• Missed dose (anxiety): The NHS says take it if less than 3 hours late; otherwise skip it. Never take two doses to make up.

Follow the money: who makes it and who funded the evidence

Ownership chain

• 1977 and 1980: The FDA approves Ativan tablets (NDA 017794, 30 September 1977) and Ativan injection (NDA 018140, 25 July 1980) (Drugs@FDA; openFDA).
• By 2007: The tablet label names Wyeth Pharmaceuticals Inc. (Philadelphia, US) as manufacturer and Biovail Pharmaceuticals, Inc. (Bridgewater, New Jersey) as distributor (2007 label). We did not trace the transfer of rights between these companies to a primary document.
• Today (tablets): Bausch Health US, LLC distributes Ativan tablets, made by Bausch Health Companies Inc. in Canada (FDA label). Bausch Health Companies Inc. is incorporated in British Columbia with headquarters in Laval, Quebec, Canada. Its filings show it was previously named Valeant Pharmaceuticals International, Inc. (Bausch Health 10-K FY2025).
• Today (injection): Hikma Pharmaceuticals USA Inc. (Berkeley Heights, New Jersey) holds and makes Ativan injection (FDA injection label).
• UK: Supplied as generics. The eMC lists 12 lorazepam products from nine companies, including Genus Pharmaceuticals (Huddersfield, UK), Zentiva, ADVANZ Pharma, Neuraxpharm and Macure Pharma (Copenhagen, Denmark) (eMC).

Revenue

Bausch Health lists Ativan among its "principal products" in its neuroscience line but does not report a sales figure for it. Its FY2025 filing mentions "lower gross product sales" of Ativan among several older branded products (Bausch Health 10-K). With 16 generic applications on file in the US (openFDA) and only generics listed in the UK, most lorazepam is sold by companies with no stake in the brand. That lowers the commercial pressure on today's evidence base.

Who funded the evidence

• Status epilepticus: The best trials were publicly funded. Alldredge 2001 received a US Public Health Service R01 grant; RAMPART was funded by the National Institute of Neurological Disorders and Stroke; Chamberlain 2014 was funded through NICHD and federal maternal and child health grants (Europe PMC; NEJM abstract; Europe PMC). The Cochrane reviews are produced under a policy that bars commercial funding (Cochrane policy). Only the two licensing trials on the injection label were sponsor-generated.
• Anxiety: The tablet label contains no trial data. The class-level evidence comes from independent syntheses (Cochrane; Slee 2019, which had no funding), which pooled mostly older, often industry-run trials. The lorazepam-specific data we found came from another company's pregabalin programme, where lorazepam was the comparator.
• Pre-operative use: The main modern trial was run by French public teaching hospitals. No commercial funder was identified.
• Regulators: 77% of FDA human-drug review costs in FY2025 came from industry user fees (FDA PDUFA report). The boxed warnings nonetheless run against commercial interest.

Integrity events: We found no sourced regulatory enforcement action specific to Ativan marketing in the documents fetched for this review. We do not infer one.

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• Stress, anxiety and depression: prevention and management guide
• Supplements for stress, anxiety and depression: the evidence
• Sleep: prevention and management guide
• Sleep supplements: the evidence
• L-theanine
• Magnesium

Sibling medicine reviews:

• Alprazolam (Xanax)
• Diazepam
• Clonazepam
• Temazepam
• Pregabalin
• Sertraline
• Escitalopram
• Zopiclone

Frequently asked questions

Sources and funding notes

• FDA-approved prescribing information and Medication Guide, Ativan (lorazepam) tablets (DailyMed, revised 07/2025): US regulator-approved label held by Bausch Health (Canada).
• FDA-approved prescribing information, Ativan (lorazepam) injection (DailyMed, revised January 2023): US label held by Hikma Pharmaceuticals USA. Efficacy data from the sponsor's trials.
• Loreev XR (lorazepam extended-release) label: US label held by Almatica Pharma.
• Drugs@FDA, NDA 017794 and archived 2007 Ativan label: US FDA records.
• openFDA: NDA 018140, NDA 214826 and generic lorazepam applications: US government open data.
• Lorazepam 1mg Tablets, UK Summary of Product Characteristics (Genus Pharmaceuticals, revised 19 March 2026): MHRA-approved; generic licence holder (UK).
• Lorazepam Macure 4 mg/ml solution for injection, UK SmPC: MHRA-approved; licence holder Macure Pharma ApS (Denmark).
• Electronic Medicines Compendium (eMC) listing for lorazepam: UK product-information database run by Datapharm.
• NHS: Lorazepam (all sections): UK NHS patient information, last reviewed 14 February 2023.
• FDA Drug Safety Communication, 23 September 2020 (benzodiazepine boxed warning): US regulator.
• FDA Drug Safety Communication, August 2016 (opioids plus benzodiazepines), archived copy: US regulator.
• MHRA Drug Safety Update, 18 March 2020: UK regulator.
• NICE NG217, Epilepsies in children, young people and adults, section 7: UK public body funded by the Department of Health and Social Care.
• NICE CG113, Generalised anxiety disorder and panic disorder in adults: UK public body.
• NICE NG215, Medicines associated with dependence or withdrawal symptoms (2022): UK public body.
• WHO mhGAP guideline, 3rd edition, 2023: World Health Organization (international). Recommendation ANX6.
• Prasad et al., Cochrane 2014, Anticonvulsant therapy for status epilepticus: Cochrane; AIIMS New Delhi (India). "None known" conflicts.
• McTague et al., Cochrane 2018, Drug management for acute tonic-clonic convulsions in children: Cochrane; UCL Great Ormond Street (UK). Two authors had worked on included trials (declared).
• Alldredge et al., NEJM 2001, Lorazepam, diazepam and placebo for out-of-hospital status epilepticus: University of California (US); US Public Health Service grant (Europe PMC).
• Silbergleit et al. (RAMPART), NEJM 2012, Intramuscular versus intravenous therapy for prehospital status epilepticus: US Neurological Emergencies Treatment Trials network; funded by NINDS and others.
• Chamberlain et al., JAMA 2014, Lorazepam vs diazepam for pediatric status epilepticus: PECARN (US/Canada); NICHD and federal grants (Europe PMC).
• Maurice-Szamburski et al., JAMA 2015, Sedative premedication and patient experience after general anaesthesia (PremedX): French public teaching hospitals. No funder named in the abstract.
• Breilmann et al., Cochrane 2019, Benzodiazepines versus placebo for panic disorder in adults: Cochrane (Germany/Italy). One author declared pharma lecture fees.
• Guaiana et al., Cochrane 2023, Pharmacological treatments in panic disorder: network meta-analysis: Cochrane (international). Some authors declared fees from Eli Lilly, Pfizer, Otsuka and others.
• Slee et al., Lancet 2019, Pharmacological treatments for GAD: network meta-analysis: University College London (UK). "No funding was received."
• Shinfuku et al., Int Clin Psychopharmacol 2019, Long-term benzodiazepine use in anxiety disorders: Keio University (Japan). No funding statement in the PubMed record.
• Lydiard et al., Int J Neuropsychopharmacol 2010, Pregabalin and benzodiazepines in GAD (pooled analysis): US authors; data from pregabalin trials. No funding statement in the abstract.
• American Geriatrics Society 2023 Updated Beers Criteria: US professional society; "no sponsor".
• GOV.UK: Drug driving (limits table) and GOV.UK: Drugs and driving, the law: UK government.
• Home Office: List of most commonly encountered controlled drugs: UK government.
• Bausch Health Companies Inc., Form 10-K for fiscal 2025: manufacturer's statutory SEC filing (Canada/US). The company's own account.
• FDA PDUFA financial report FY2025: US government. Source of the user-fee share figure.
• Cochrane commercial sponsorship policy: Cochrane (UK/international).

Last reviewed: 26 September 2026. Educational information from Pure City Research, not medical advice. Medicine decisions belong with a qualified prescriber.